Literature DB >> 2460372

Adenosine 3',5'-cyclic monophosphate (cAMP) inhibits phorbol ester-induced growth of an IL-2-dependent T cell line.

Y Goto1, T Takeshita, K Sugamura.   

Abstract

We previously established a human T cell line, TPA-Mat, which can proliferate in response to not only interleukin-2 (IL-2), but also phorbol esters such as 12-O-tetradecanoylphorbol-13-acetate (TPA) and phorbol-12,13-dibutyrate (PDBu). The present study demonstrated that the PDBu-dependent growth of TPA-Mat cells was inhibited up to 90% by adenosine 3',5'-cyclic monophosphate (cAMP] raising agents such as forskolin, cholera toxin and 1-methyl-3-isobutyl-xanthine, and cAMP analogues, whereas the IL-2-stimulated TPA-Mat growth was slightly inhibited. These findings suggest that the signal transduction pathway of PDBu-induced growth, which should involve activation of protein kinase C, is sensitive to cAMP, and that it cannot be exactly identical to the signal transduction pathway of Il-2-induced growth in TPA-Mat cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2460372     DOI: 10.1016/0014-5793(88)80909-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  Effects of cyclic nucleotides and phorbol myristate acetate on proliferation of pig aortic endothelial cells.

Authors:  S A Moodie; W Martin
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

2.  Expression of p55 (Tac) interleukin-2 receptor (IL-2R), but not p75 IL-2R, in cultured H-RS cells and H-RS cells in tissues.

Authors:  S M Hsu; C K Tseng; P L Hsu
Journal:  Am J Pathol       Date:  1990-04       Impact factor: 4.307

3.  Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2.

Authors:  M A Giembycz; C J Corrigan; J Seybold; R Newton; P J Barnes
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.